ST elevation myocardial infarction anticoagulant and antithrombotic therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 30: | Line 30: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
{{SIB}} | {{SIB}} | ||
Revision as of 23:53, 21 April 2009
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Sites of Action of Antithrombins
The majority of established and investigational antithrombins [1] target two factors in the coagulation cascade: Factor Xa and Factor II.
Parenteral Drugs Targeting Factor Xa
Idraparinux
Oral Drugs Targeting Factor Xa
Rivaroxaban
Apixaban
LY517717
YM150
DU-176b
PRT-054021
References
- ↑ Weitz JI (2006). "Emerging anticoagulants for the treatment of venous thromboembolism". Thromb. Haemost. 96 (3): 274–84. doi:10.1160/TH06-05-0234. PMID 16953267. Unknown parameter
|month=ignored (help)